Agree with that, think its a money grab for a lot of them, and they just want to keep getting paid for years without achieving. Unless something changes—we’re stuck funding their luxury lifestyles while they avoid doing the very thing they’re paid to do: deliver results.
As Ive said without being incentivised for the shareprice to do well, It’s actually better for these doctors and execs to keep the company limping along rather than taking a real risk. If they take a big swing and fail, the gravy train ends. But if they drag their feet, string shareholders along with endless "progress updates," and avoid any decisive moves, they can milk the company for millions over years.
Why push for a breakthrough when slow-walking everything ensures fat salaries, performance rights, and a cozy job for the foreseeable future? It’s a broken system that punishes shareholders and rewards complacency.
Paul Hopper (IMU’s Executive Chair and Director) is involved with a few ASX biotechs, getting paid millions out of their accounts and awarded mllions in performance rights. He's a multimillionaire from the companies, but they are all down 90% or more in the last few years, so shareholders left with nothing yet again.
IMU Price at posting:
3.6¢ Sentiment: Hold Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)